NewAmsterdam Pharma Company N.V. $NAMS Shares Purchased by Nicholas Investment Partners LP

Nicholas Investment Partners LP lifted its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 20.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 213,419 shares of the company’s stock after purchasing an additional 35,881 shares during the period. Nicholas Investment Partners LP owned approximately 0.19% of NewAmsterdam Pharma worth $7,487,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in NAMS. Farther Finance Advisors LLC increased its holdings in NewAmsterdam Pharma by 4,425.0% during the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after acquiring an additional 708 shares in the last quarter. Wells Fargo & Company MN increased its holdings in NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after acquiring an additional 300 shares in the last quarter. Navalign LLC purchased a new position in NewAmsterdam Pharma during the 4th quarter valued at about $46,000. Empowered Funds LLC purchased a new position in NewAmsterdam Pharma during the 4th quarter valued at about $85,000. Finally, NBC Securities Inc. purchased a new position in NewAmsterdam Pharma during the 4th quarter valued at about $86,000. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the transaction, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at $869,158.57. The trade was a 72.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 12.74% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Stock Performance

NewAmsterdam Pharma stock opened at $30.40 on Friday. NewAmsterdam Pharma Company N.V. has a 1 year low of $17.63 and a 1 year high of $42.21. The firm has a 50 day moving average price of $33.44 and a 200 day moving average price of $33.69. The company has a market cap of $3.55 billion, a price-to-earnings ratio of -16.98 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. The business had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. Sell-side analysts predict that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Guggenheim lifted their price target on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Truist Financial began coverage on shares of NewAmsterdam Pharma in a report on Wednesday, March 18th. They set a “buy” rating and a $57.00 price target for the company. Finally, HC Wainwright upgraded shares of NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $48.60.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.